Siddique Maimoona, Hassan Aamna, Nawaz Muhammad Khalid, Bashir Humayun, Chaudhry Muhammad Zulqarnain
Department of Nuclear Medicine, Pakistan Kidney and Liver Institute and Research Centre, Lahore, Pakistan.
Department of Nuclear Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
World J Nucl Med. 2020 Jan 29;19(1):21-27. doi: 10.4103/wjnm.WJNM_23_19. eCollection 2020 Jan-Mar.
To compare the detection efficacy of radionuclide lymphoscintigraphy (LS) versus patent blue dye (PBD) technique for hidden sentinel lymph node (SLN) in breast cancer patients and to determine which modality is better for SLN detection. One hundred and thirty-four early stage breast cancer female patients with clinically negative axilla who underwent post technetium-99m nanocolloid injection single photon emission computed tomography (SPECT-CT) for negative SLN on planar imaging were studied prospectively between 2015 and 2017. Following SPECT-CT, patients underwent peroperative gamma probe count detection GP-CD and PBD technique. Visually, blue stained ± hot nodes were surgically removed and subjected to histopathological analysis. The detection rate by individual method was calculated. Kappa statistics were applied to calculate overall agreement between radioisotope and PBD techniques for diagnostic value assessment. One hundred and thirty-four patients underwent SPECT-CT LS and PBD injection. Mean age: 47 ± 7.6 years (range: 26-82 years). Forty-nine (36.6%) had T1 and 85 (63.4%) T2. SPECT-CT LS detected SLN in 105/134 cases (success rate: 78.4%), later GP-CD localized "hot nodes" in additional 20 cases (success rate: 93.3%). The PBD successfully localized SLN in 131/134 (97.8%) cases. Three cases remained negative on both radioisotope and PBD localization, which on subsequent nodal dissection had metastatic disease. All SLNs detected on SPECT-CT showed blue dye uptake. In 112 cases, more than one SLN was surgically removed. Frozen section analysis of excised SLNs showed metastasis in 31%. Overall moderate agreement (k = 0.56) was calculated. No statistically significant difference was seen between isotope detection and PBD. Radionuclide sentinel mapping has good detection rate particularly combined with peroperative GP-CD. The PBD has added value to reduce false-negative rate of SLN mapping and can substitute radionuclide imaging with negative results.
比较放射性核素淋巴闪烁造影(LS)与专利蓝染料(PBD)技术对乳腺癌患者隐匿前哨淋巴结(SLN)的检测效果,并确定哪种方式更适合检测SLN。对2015年至2017年期间前瞻性研究的134例临床腋窝阴性的早期乳腺癌女性患者进行研究,这些患者在注射99m锝纳米胶体后进行单光子发射计算机断层扫描(SPECT-CT),平面成像显示SLN为阴性。在SPECT-CT之后,患者接受术中γ探测计数检测(GP-CD)和PBD技术。肉眼可见,蓝色染色的±热点淋巴结被手术切除并进行组织病理学分析。计算每种方法的检测率。应用Kappa统计量计算放射性同位素和PBD技术之间在诊断价值评估方面的总体一致性。134例患者接受了SPECT-CT LS和PBD注射。平均年龄:47±7.6岁(范围:26-82岁)。49例(36.6%)为T1期,85例(63.4%)为T2期。SPECT-CT LS在105/134例中检测到SLN(成功率:78.4%),随后GP-CD在另外20例中定位到“热点淋巴结”(成功率:93.3%)。PBD在131/134例(97.8%)中成功定位到SLN。3例在放射性同位素和PBD定位中均为阴性,随后的淋巴结清扫显示有转移性疾病。在SPECT-CT上检测到的所有SLN均显示有蓝色染料摄取。在112例中,手术切除了一个以上的SLN。切除的SLN的冰冻切片分析显示转移率为31%。计算得出总体一致性为中等(k = 0.56)。同位素检测和PBD之间未观察到统计学上的显著差异。放射性核素前哨淋巴结定位具有良好的检测率,特别是与术中GP-CD联合使用时。PBD对于降低SLN定位的假阴性率具有附加价值,并且可以替代结果为阴性的放射性核素成像。